Literature DB >> 13463102

Influence of cortisone and prednisolone on hyperbilirubinemia.

R KATZ, H DUCCI, H ALESSANDRI.   

Abstract

Entities:  

Keywords:  BILIRUBIN/in blood; CORTISONE/effects; PREDNISOLONE/effects

Mesh：

Substances：

Year:  1957        PMID： 13463102      PMCID： PMC1072735          DOI： 10.1172/JCI103536

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  9 in total

1.  Cortisone in the treatment of infectious hepatitis.

Authors:  T E HUBER; A T WILEY
Journal:  Ann Intern Med       Date:  1955-05       Impact factor: 25.391

2.  Evaluation of a four-day ACTH test in the differential diagnosis of jaundice.

Authors:  T C CHALMERS; R J GILL; T P JERNIGAN; F A SVEC; R S JORDAN; S S WALDSTEIN; M KNOWLTON
Journal:  Gastroenterology       Date:  1956-06       Impact factor: 22.682

3.  Intrahepatic obstructive jaundice (primary cholestasis), a clinicopathologic syndrome of varied etiology: a review with observations of the use of corticotropin as a diagnostic tool.

Authors:  H C JOHNSON; J P DOENGES
Journal:  Ann Intern Med       Date:  1956-04       Impact factor: 25.391

4.  Choleretic action of cortisone.

Authors:  P R PATTERSON; J F DINGMAN; H SHWACHMAN; G W THORN
Journal:  N Engl J Med       Date:  1954-09-23       Impact factor: 91.245

5.  [Treatment of epidemic hepatitis with cortisone].

Authors:  W SIEGENTHALER; L SUTER
Journal:  Schweiz Med Wochenschr       Date:  1955-10-22

6.  ACTH therapy in acute viral hepatitis.

Authors:  V M SBOROV; B GIGES; I C PLOUGH; W MANDEL
Journal:  J Lab Clin Med       Date:  1954-01

7.  The course of icterus index and prothrombin value during corticotropin treatment of acute hepatitis and obstructive jaundice; a preliminary report.

Authors:  J H SOLEM; A OLSEN
Journal:  Acta Med Scand       Date:  1953

8.  Adrenal hormone therapy in viral hepatitis. I. The effect of ACTH in the acute disease.

Authors:  A S EVANS; H SPRINZ; R S NELSON
Journal:  Ann Intern Med       Date:  1953-06       Impact factor: 25.391

9.  [Fulminant hepatitis; recovery].

Authors:  H DUCCI; J MOTLIS
Journal:  Rev Med Chil       Date:  1951-09       Impact factor: 0.553
  9 in total
  11 in total

1.  Corticotrophin and steroids in the diagnosis and management of obstructive jaundice.

Authors:  W H SUMMERSKILL; F A JONES
Journal:  Br Med J       Date:  1958-12-20

2.  [Neuroplegia ("vegetative blockade") as a therapeutic principle for the injured newborn infant].

Authors:  H G BACH
Journal:  Arch Gynakol       Date:  1960

3.  Discussion on endocrine changes in liver disease.

Authors:  S SHERLOCK; J LEE; G W BISSET; W H SUMMERSKILL
Journal:  Proc R Soc Med       Date:  1958-05

4.  HORMONES and liver disease.

Authors: 
Journal:  Br Med J       Date:  1958-02-01

Review 5.  [Hemoglobin metabolism and bilirubin formation].

Authors:  D Gemsa; R Schmid
Journal:  Klin Wochenschr       Date:  1974-07-01

6.  Effect of corticosteroid therapy on bromsulphthalein excretion in active chronic hepatitis.

Authors:  G C Cook; M Velasco; S Sherlock
Journal:  Gut       Date:  1968-06       Impact factor: 23.059

7.  Diagnosis and treatment of cholangiolitic hepatitis (primary biliary cirrhosis).

Authors:  W P Longmire; W L Joseph; P M Levin; S M Mellinkoff
Journal:  Ann Surg       Date:  1965-09       Impact factor: 12.969

8.  Betamethasone in plus phenobarbitone prior to hepatobiliary scintigraphy increases diagnostic accuracy in infants with jaundice.

Authors:  D K Gupta; A R Charles; M Srinivas; S Dave; C S Bal
Journal:  Indian J Pediatr       Date:  2001-11       Impact factor: 1.967

9.  Hydrocortisone choleresis in the dog.

Authors:  V Macarol; T Q Morris; K J Baker; S E Bradley
Journal:  J Clin Invest       Date:  1970-09       Impact factor: 14.808

10.  Erythrocyte catabolism by macrophages in vitro. The effect of hydrocortisone on erythrophagocytosis and on the induction of heme oxygenase.

Authors:  C Gemsa; C H Woo; H H Fudenberg; R Schmid
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.